<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Rehulka J</submitter><funding>National Institute for Cancer Research</funding><funding>CZ-OPENSCREEN</funding><funding>EATRIS-CZ</funding><funding>Ministry of Education, Youth and Sports of the Czech Republic through the e-INFRA CZ</funding><funding>EXCELES</funding><funding>UCT Prague</funding><pagination>2367139</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC467089</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>39(1)</volume><pubmed_abstract>Estradiol dimers (EDs) possess significant anticancer activity by targeting tubulin dynamics. In this study, we synthesised 12 EDs variants via copper-catalysed azide-alkyne cycloaddition (CuAAC) reaction, focusing on structural modifications within the aromatic bridge connecting two estradiol moieties. &lt;i>In vitro&lt;/i> testing of these EDs revealed a marked improvement in selectivity towards cancerous cells, particularly for ED1-8. The most active compounds, ED3 (IC&lt;sub>50&lt;/sub> = 0.38 μM in CCRF-CEM) and ED5 (IC&lt;sub>50&lt;/sub> = 0.71 μM in CCRF-CEM) demonstrated cytotoxic effects superior to 2-methoxyestradiol (IC&lt;sub>50&lt;/sub> = 1.61 μM in CCRF-CEM) and exhibited anti-angiogenic properties in an endothelial cell tube-formation model. Cell-based experiments and &lt;i>in vitro&lt;/i> assays revealed that EDs interfere with mitotic spindle assembly. Additionally, we proposed an &lt;i>in silico&lt;/i> model illustrating the probable binding modes of ED3 and ED5, suggesting that dimers with a simple linker and a single substituent on the aromatic central ring possess enhanced characteristics compared to more complex dimers.</pubmed_abstract><journal>Journal of enzyme inhibition and medicinal chemistry</journal><pubmed_title>Click estradiol dimers with novel aromatic bridging units: synthesis and anticancer evaluation.</pubmed_title><pmcid>PMC467089</pmcid><funding_grant_id>A1_FPBT_2023_003</funding_grant_id><funding_grant_id>90254</funding_grant_id><funding_grant_id>LX22NPO5102</funding_grant_id><funding_grant_id>LM2023052</funding_grant_id><funding_grant_id>LM2023053</funding_grant_id><funding_grant_id>IGA_LF_2024_038</funding_grant_id><pubmed_authors>Ivanova A</pubmed_authors><pubmed_authors>Gurska S</pubmed_authors><pubmed_authors>Polishchuk P</pubmed_authors><pubmed_authors>Rehulka J</pubmed_authors><pubmed_authors>Drasar PB</pubmed_authors><pubmed_authors>Draber P</pubmed_authors><pubmed_authors>Dzubak P</pubmed_authors><pubmed_authors>Jecmenova K</pubmed_authors><pubmed_authors>Hajduch M</pubmed_authors><pubmed_authors>Jurasek M</pubmed_authors><pubmed_authors>Mokshyna O</pubmed_authors></additional><is_claimable>false</is_claimable><name>Click estradiol dimers with novel aromatic bridging units: synthesis and anticancer evaluation.</name><description>Estradiol dimers (EDs) possess significant anticancer activity by targeting tubulin dynamics. In this study, we synthesised 12 EDs variants via copper-catalysed azide-alkyne cycloaddition (CuAAC) reaction, focusing on structural modifications within the aromatic bridge connecting two estradiol moieties. &lt;i>In vitro&lt;/i> testing of these EDs revealed a marked improvement in selectivity towards cancerous cells, particularly for ED1-8. The most active compounds, ED3 (IC&lt;sub>50&lt;/sub> = 0.38 μM in CCRF-CEM) and ED5 (IC&lt;sub>50&lt;/sub> = 0.71 μM in CCRF-CEM) demonstrated cytotoxic effects superior to 2-methoxyestradiol (IC&lt;sub>50&lt;/sub> = 1.61 μM in CCRF-CEM) and exhibited anti-angiogenic properties in an endothelial cell tube-formation model. Cell-based experiments and &lt;i>in vitro&lt;/i> assays revealed that EDs interfere with mitotic spindle assembly. Additionally, we proposed an &lt;i>in silico&lt;/i> model illustrating the probable binding modes of ED3 and ED5, suggesting that dimers with a simple linker and a single substituent on the aromatic central ring possess enhanced characteristics compared to more complex dimers.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Dec</publication><modification>2026-04-29T12:12:19.215Z</modification><creation>2025-04-06T17:10:50.957Z</creation></dates><accession>S-EPMC467089</accession><cross_references><pubmed>38904149</pubmed><doi>10.1080/14756366.2024.2367139</doi></cross_references></HashMap>